TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) 3220-95461
In re Application of: Stanton B. Gelvin	
Application No.: 10/766,389	
Filed: January 26, 2004	
For: Enhanced Plant Cell Transformation By Addition Of Host Genes Involved In T-DNA Integration	
The owner*, <u>Purcus Research Foundation</u> of <u>100</u> percent interest in the institutory term of any patient granted on the institutory term of any patient granted on the institution of <u>100</u> percent interest in the institution of the statutory term of any patient granted on the institution of <u>100</u> percent any patient granted on the institution of <u>100</u> percent granted on the institution of <u>100</u> percent granted on the institution of <u>100</u> percent granted on the institution of the grant of any patient on the pending parated on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the reference application are commonly owned.	ation which would extend beyond 10/664,658 filed patent granted on said reference reference application. The owner such pedad that it and any patent
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any pro- application, "as the term of any patent granted on said reference application may be shortened by any termination of any patent on the pending reference application," in the event that any such patent; granted on the expires for failure to pay a maintenance fee, is hed unenforceable, is found invalid by a court of competent; in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer field prior to	atent granted on said reference minal disclaimer filed prior to the pending reference application: insdiction, is statutorily disclaimed a is relessed on is in any manner
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, gove etc.), the undersigned is empowered to act on behalf of the business/organization.	ernment agency,
I hereby declare that all statements made herein of my own knowledge are true and that all state belief are believed to be true; and further that these statements were made with the knowledge that willful made are punishable by fine or impressment, or both, under Section 1001 of Title 18 of the United States statements may jeopardize the validity of the application or any patient issued thereon.	false statements and the like or
2.  The undersigned is an attorney or agent of record. Reg. No. 35,601	
Asia D. Woeler	6/6/01 Date
Alice O. Martin	
Typed or printed name	
	312-214-8316 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	receptions nulliber

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

From P1 (U)Schlor may be used for making this statement, See MPEP § 324.

This collection of information is required by 37 CPR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) an application. Confidentially is governed by 30 U.S.C. 1.22 and 37 CPR 1.11 and 1.14. This collection is estimated to take 12 ninutes to complete, to proceed the confidentially is governed by 30 U.S.C. 1.22 and 37 CPR 1.11 and 1.14. This collection is estimated to take 12 ninutes to complete, the second is a confidentially as the confidential of the

## Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Tradamark Office: U.S. DEPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional) REJECTION OVER A "PRIOR" PATENT 3220-95461 In re Application of: Stanton B. Gelvin Application No.: 10/766,389 Filed: January 26, 2004 For Enhanced Plant Cell Transformation By Addition Of Host Genes Involved In T-DNA Integration The owner", <u>Purdua Research Foundation</u> of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patient granted on the Iristant application which would extend beyond the expraint of all the full statutory term prior patient (Fig. 10, U.S., 125, 125, 13). and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later. expires for failure to pay a maintenance fee; is held unenforceable: is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate: is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Reg. No. Alice O. Martin yped or printed name 312-214-8316 Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the complated application form to the USPTO. Time will vary depending upon the individual case. Any comments on anount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Christ Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1494, (Aswarding, V.A. 2301-3409, DO NOT SEND PEES OR COMPILETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,